CLINICAL TRIALS PROFILE FOR SEMAXANIB
✉ Email this page to a colleague
Clinical Trials for Semaxanib
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00003720 ↗ | SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma | Completed | Pfizer | Phase 1 | RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma. |
NCT00004252 ↗ | Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer | Completed | Pfizer | Phase 3 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known whether chemotherapy is more effective with or without SU5416 in treating metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of leucovorin and fluorouracil with or without SU5416 in treating patients who have metastatic colorectal cancer. |
NCT00004868 ↗ | SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy. |
NCT00004868 ↗ | SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy | Completed | North American Brain Tumor Consortium | Phase 1/Phase 2 | RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy. |
NCT00004868 ↗ | SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/Phase 2 | RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy. |
NCT00005042 ↗ | SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Semaxanib
Condition Name
Clinical Trial Locations for Semaxanib
Trials by Country
Clinical Trial Progress for Semaxanib
Clinical Trial Phase
Clinical Trial Sponsors for Semaxanib
Sponsor Name